Literature DB >> 23023736

Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia.

Ayami Yoshimi1, Yoshiro Kamachi, Kosuke Imai, Nobuhiro Watanabe, Hisaya Nakadate, Takashi Kanazawa, Shuichi Ozono, Ryoji Kobayashi, Misa Yoshida, Chie Kobayashi, Asahito Hama, Hideki Muramatsu, Yoji Sasahara, Marcus Jakob, Tomohiro Morio, Stephan Ehl, Atsushi Manabe, Charlotte Niemeyer, Seiji Kojima.   

Abstract

BACKGROUND: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by defects of the WAS protein (WASP) gene. Patients with WAS typically demonstrate micro-thrombocytopenia. PROCEDURES: The report describes seven male infants with WAS that initially presented with leukocytosis, monocytosis, and myeloid and erythroid precursors in the peripheral blood (PB) and dysplasia in the bone marrow (BM), which was initially indistinguishable from juvenile myelomonocytic leukaemia (JMML).
RESULTS: The median age of affected patients was 1 month (range, 1-4 months). Splenomegaly was absent in four of these patients, which was unusual for JMML. A mutation analysis of genes in the RAS-signalling pathway did not support a diagnosis of JMML. Non-haematological features, such as eczema (n = 7) and bloody stools (n = 6), ultimately led to the diagnosis of WAS at a median age of 4 months (range, 3-8 months), which was confirmed by absent (n = 6) or reduced (n = 1) WASP expression in lymphocytes by flow cytometry (FCM) and a WASP gene mutation. Interestingly, mean platelet volume (MPV) was normal in three of five patients and six of seven patients demonstrated occasional giant platelets, which was not compatible with WAS.
CONCLUSIONS: These data suggest that WAS should be considered in male infants presenting with JMML-like features if no molecular markers of JMML can be detected.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023736     DOI: 10.1002/pbc.24359

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

Review 1.  Primary immunodeficiencies and their associated risk of malignancies in children: an overview.

Authors:  Samuele Renzi; Karin Petra Sabine Langenberg-Ververgaert; Nicolas Waespe; Salah Ali; Jack Bartram; Orli Michaeli; Julia Upton; Michaela Cada
Journal:  Eur J Pediatr       Date:  2020-03-11       Impact factor: 3.183

2.  Wiskott-Aldrich syndrome protein senses irradiation-induced DNA damage to coordinate the cell-protective Golgi dispersal response in human T and B lymphocytes.

Authors:  Kuo-Kuang Wen; Seong-Su Han; Yatin M Vyas
Journal:  J Allergy Clin Immunol       Date:  2019-10-09       Impact factor: 10.793

3.  Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.

Authors:  Christopher C Dvorak; Prakash Satwani; Elliot Stieglitz; Mitchell S Cairo; Ha Dang; Qinglin Pei; Yun Gao; Donna Wall; Tali Mazor; Adam B Olshen; Joel S Parker; Samir Kahwash; Betsy Hirsch; Susana Raimondi; Neil Patel; Micah Skeens; Todd Cooper; Parinda A Mehta; Stephan A Grupp; Mignon L Loh
Journal:  Pediatr Blood Cancer       Date:  2018-03-12       Impact factor: 3.167

Review 4.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 5.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

6.  Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases.

Authors:  Hamilton C Tsang; James B Bussel; Susan Mathew; Yen-Chun Liu; Allison A Imahiyerobo; Attilio Orazi; Julia T Geyer
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

Review 7.  Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.

Authors:  Fabio Candotti
Journal:  J Clin Immunol       Date:  2017-10-30       Impact factor: 8.542

8.  The genomic landscape of juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Amaro N Taylor-Weiner; Tiffany Y Chang; Laura C Gelston; Yong-Dong Wang; Tali Mazor; Emilio Esquivel; Ariel Yu; Sara Seepo; Scott Olsen; Mara Rosenberg; Sophie L Archambeault; Ghada Abusin; Kyle Beckman; Patrick A Brown; Michael Briones; Benjamin Carcamo; Todd Cooper; Gary V Dahl; Peter D Emanuel; Mark N Fluchel; Rakesh K Goyal; Robert J Hayashi; Johann Hitzler; Christopher Hugge; Y Lucy Liu; Yoav H Messinger; Donald H Mahoney; Philip Monteleone; Eneida R Nemecek; Philip A Roehrs; Reuven J Schore; Kimo C Stine; Clifford M Takemoto; Jeffrey A Toretsky; Joseph F Costello; Adam B Olshen; Chip Stewart; Yongjin Li; Jing Ma; Robert B Gerbing; Todd A Alonzo; Gad Getz; Tanja Gruber; Todd Golub; Kimberly Stegmaier; Mignon L Loh
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

Review 9.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418

Review 10.  Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.

Authors:  David Buchbinder; Diane J Nugent; Alexandra H Fillipovich
Journal:  Appl Clin Genet       Date:  2014-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.